Summary To evaluate the risk of endometrial cancer subsequent to breast cancer, a case-control study was carried out in Denmark. Between 1943Between -1977 (Schoenberg, 1977; Kelsey & Hildreth, 1983) . This may reflect a common aetiology of the two cancers (Armstrong, 1979) as well as the influence of various treatments for breast cancer (Hoover et al., 1976 
Several studies indicate that breast cancer patients have an increased risk of developing subsequent endometrial cancer (Schoenberg, 1977; Kelsey & Hildreth, 1983) . This may reflect a common aetiology of the two cancers (Armstrong, 1979) as well as the influence of various treatments for breast cancer (Hoover et al., 1976) . Such therapies include irradiation to the pelvic area and sex hormones, especially oestrogen.
The risk of endometrial cancer associated with oestrogen therapy for breast cancer was previously investigated in a cohort analysis by Hoover et al. (1976) . They reported a 3-and 2-fold increase in risk, respectively, when oestrogens were given during an initial or subsequent course of breast cancer treatment. Their data on oestrogen use, however, derived from information in cancer registry records, and all treatments classified as "hormones" were presumed to be oestrogens. Moreover, no specification of type of oestrogen, dose and duration of treatment was available.
A case-control study of endometrial cancer in women previously diagnosed with breast cancer, conducted simultaneously in Denmark and USA, was initiated to evaluate further the risk associated with oestrogen therapy and other factors suspected to affect the risk of endometrial cancer. This paper communicates the results of the Danish series. Comparisons between cases and matched controls for all variables of interest were made by the conditional logistic regression methods described in Breslow & Day (1980) . The computer program used (Lubin, 1981) were combined. However, none of the relative risks were significantly different from unity (Table IV) . Radiation to the breast and axilla did not affect the risk of developing endometrial cancer. The risk associated with personal characteristics and exposure to drugs was examined in relation to age at which the cases developed endometrial cancer. No appreciable differences between women aged 65 years or more and younger women were observed for most factors, although there was a suggestion that the relative risk was higher for menopausal oestrogen use among older (RR=7.8; 95% CI: 2.4-25) than younger women (RR=2.6, 95% CI: 1.1-6.6).
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In the absence of a previous diagnosis of breast cancer the most consistently reported risk factors for endometrial cancer are nulliparity, late age at menopause, obesity, and oestrogens for menopausal symptoms (Elwood et al., 1977; Ewertz, 1981; Kelsey et al., 1982; La Vecchia et al., 1982; MacMahon, 1974; Salmi, 1979; Wynder et al., 1966) . Our results closely agree with those studies. This consistency suggests that studies of second primary cancers have the potential to provide information on risk factors other than those associated with therapy. The epidemiology of breast and endometrial cancer appear similar in many respects, and both the geographical correlation of these two malignancies and the frequency of occurrence within the same individual suggest that they may have aetiologic factors in common (Kelsey & Hildreth, 1983) . Such factors include nulliparity, obesity, and late menopause, possibly mediated by a hormonal mechanism (Henderson et al., 1982) .
These are associated with an increased breast cancer risk and were, in the present study, associated with increased risk of endometrial cancer. Interestingly, since both cases and controls had breast cancer, an inadvertant "overmatching" on these common factors was possible. However, any overmatching would tend to reduce the estimates of the relative risk, and the "true" associations would be even stronger than observed.
One of the main purposes of the study was to examine the risk of endometrial cancer in relation to exogenous oestrogens. Our results on usage for menopausal symptoms with five-to eight-fold increases in relative risk, depending on duration of use, agree well with what is reported in the literature (Kelsey & Hildreth, 1983) . Duration of use probably also explains that the oestrogen associated risk was higher among older women, since these women used oestrogens for longer periods than the younger ones. The age effect is unlikely to be due to confounding by menopausal age, because adjustment for this factor did not alter the risks significantly.
We find it puzzling that no elevated risk was clearly associated with oestrogen treatment for breast cancer, but this may be due to the low doses and short durations of treatment involved. When short term users are excluded, i.e. those with a duration of use less than one year, the relative risk increased to 1.7, but the calculation was based on small numbers. This relative risk is also compatible with that obtained for the former study of oestrogen therapy for breast cancer (Hoover et al., 1976) . Others (Hulka et al., 1980; Kelsey et al., 1982; Shapiro et al., 1980) have shown that oestrogens must be used for a period of 2-3 years before a significant increase in risk can be detected. Information on doses of oestrogen was well documented for breast cancer therapy, but unfortunately not so for treatment of menopausal symptoms, and a comparison of dosage could not be done.
Several sources of bias might affect the association between oestrogen and endometrial cancer (Cramer & Knapp, 1979) . In the present study, information on menopausal oestrogen use was obtained almost exclusively at the time of the breast cancer diagnosis. The possibility of recall bias was thus minimal. Since the ascertainment of oestrogen use occurred at least three months prior to the diagnosis of endometrial cancer, detection bias was also unlikely.
Ionizing radiation is a well known carcinogen, and the incidence rate of almost all cancers appears to increase after irradiation (Boice, 1981) . Studies of women treated with radiation for benign gynaecological disorders (Dickson, 1969; Smith & Doll, 1976; Wagoner, 1984) and for cervical cancer (Boice et al., 1984; Dickson, 1972) have found uterine cancer to be associated with radiotherapy of the pelvis. Our results also suggest an increased risk of endometrial carcinoma following pelvic irradiation, although due to the small number of exposed women, chance could not be excluded as an alternative explanation. No effect, however, was observed for radiation to the breast and axilla.
In conclusion, this study provides some evidence that endometrial cancer following breast cancer seems to be the same disease as that developing in previously healthy women, especially with respect to the high risk associated with menopausal oestrogen use. It also gives support to the hypothesis that some common factors are likely to be involved in the aetiology of breast and endometrial cancers, in particular late age at menopause, nulliparity and obesity. Because of the small study size, it was not possible to produce a conclusive evaluation of risk associated with hormones or pelvic radiation used in breast cancer treatment. However, this may be clarified when the present data are combined with a similar study conducted in the United States.
